← Leaderboards
Meredith Hay
University Of Missouri-Columbia
$10,722,587
Attributed
$21,239,471
Total exposure
12
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,239,471 · 12
By mechanism
U01$15,294,498 · 3
R01$3,608,957 · 2
R43$2,161,116 · 5
K02$162,900 · 1
R13$12,000 · 1
Top collaborators
- John P Konhilas10 shared
- Heidi M. Mansour10 shared
- Jeremy Riley3 shared
- Todd W Vanderah3 shared
- Andrew E Arai2 shared
- Tamara Crockett2 shared
- Nina Ossanna2 shared
- Lee Ryan2 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Eileen M Hasser$9,026,232
- David Douglas Kline$9,120,421
- Kevin James Cummings$2,645,878
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposReceptorBrainImpaired CognitionCerebrovascular CirculationS Disease RiskPeptidesAgonistInflammatoryVascular Cognitive Impairment And DementiaS Disease Related DementiaDementiaVisionCognitive FunctionFormulationProductionInflammationSubcutaneousGtp-Binding ProteinsNeuronsDoseLink ProteinExhibitsOxygen
Grant awards (38)
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study$1,990,623
U01 · FY2025 · AG · contact PI
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study$1,707,517
U01 · FY2024 · AG · contact PI
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study$2,208,081
U01 · FY2023 · AG · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,535,000
U01 · FY2023 · AG · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$679,894
U01 · FY2023 · AG · contact PI
GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular$499,545
R43 · FY2023 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,145,632
U01 · FY2022 · AG · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$766,972
U01 · FY2022 · AG · contact PI
Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia$499,763
R43 · FY2022 · AG
Scale-up Manufacturing and IND Enabling Studies of Extended-Release Formulation of Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Alzheimer's Disease-Related Dementias$499,598
R43 · FY2022 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$48,092
U01 · FY2022 · AG · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,596,374
U01 · FY2021 · AG · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$380,202
U01 · FY2021 · AG · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$16,031
U01 · FY2021 · AG · contact PI
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$1,506,750
U01 · FY2020 · AG · contact PI
Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment$439,355
R43 · FY2020 · AG
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia$345,375
U01 · FY2020 · AG · contact PI
Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)$222,855
R43 · FY2019 · AG
Evaluation of the Safety and Efficacy of Angiotensin 1-7 to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery$622,890
U01 · FY2018 · HL
Evaluation of the Safety and Efficacy of Angiotensin 1-7 to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery$745,065
U01 · FY2017 · HL
Circumventricular Organs: Gender and Hypertension$349,641
R01 · FY2007 · HL · contact PI
Regulation of Baroreceptor Afferent Transmission$209,785
R01 · FY2007 · HL · contact PI
Circumventricular Organs: Gender and Hypertension$360,084
R01 · FY2006 · HL · contact PI
Regulation of Baroreceptor Afferent Transmission$216,051
R01 · FY2006 · HL · contact PI
Circumventricular Organs: Gender and Hypertension$367,500
R01 · FY2005 · HL
Circumventricular Organs: Gender and Hypertension$260,961
R01 · FY2005 · HL
Regulation of Baroreceptor Afferent Transmission$235,628
R01 · FY2005 · HL
Regulation of Baroreceptor Afferent Transmission$21,622
R01 · FY2005 · HL
Neural Mechanisms in Casdiovascular Regulation$12,000
R13 · FY2004 · HL
CIRCUMVENTRICULAR ORGANS: GENDER AND HYPERTENSION$292,283
R01 · FY2003 · HL
CIRCUMVENTRICULAR ORGANS: GENDER AND HYPERTENSION$283,772
R01 · FY2002 · HL
REGULATION OF BARORECEPTOR AFFERENT TRANSMISSION$182,332
R01 · FY2002 · HL
CIRCUMVENTRICULAR ORGANS: GENDER AND HYPERTENSION$250,415
R01 · FY2001 · HL
REGULATION OF BARORECEPTOR AFFERENT TRANSMISSION$151,719
R01 · FY2001 · HL
BARORECEPTOR NEURONS--METABOTROPIC RECEPTOR MODULATION$95,400
K02 · FY2001 · HL
CIRCUMVENTRICULAR ORGANS: GENDER AND HYPERTENSION$279,865
R01 · FY2000 · HL
REGULATION OF BARORECEPTOR AFFERENT TRANSMISSION$147,299
R01 · FY2000 · HL
BARORECEPTOR NEURONS--METABOTROPIC RECEPTOR MODULATION$67,500
K02 · FY2000 · HL